COVID-19 Research Paper Volume 14, Issue 1 pp 73—108
Decreased TMPRSS2 expression by SARS-CoV-2 predicts the poor prognosis of lung cancer patients through metabolic pathways and immune infiltration
Figure 2. Relationship between TMPRSS2 expression and clinicopathological parameters of lung cancer patients. TMPRSS2 expression was assessed in (A) male and female LUAD (normal, n = 59; male, n = 238; female, n = 276) and LUSC (normal, n = 52; male, n = 366; female, n = 128) patients, (B) patients with different stages of LUAD (normal, n = 59; stage 1, n = 277; stage 2, n = 125, stage 3, n = 85; stage 4, n = 28) and LUSC (normal, n = 52; stage 1, n = 243; stage 2, n = 157, stage 3, n = 85; stage 4, n = 7), (C) patients with different nodal metastasis statuses of LUAD (normal, n = 59; N0, n = 331; N1, n = 96, N2, n = 74; N3, n = 2) and LUSC (normal, n = 52; N0, n = 320; N1, n = 131, N2, n = 40; N3, n = 5). *p < 0.05, **p < 0.01, ***p < 0.001.